

The MetaNeb® System

Three therapies. One device.
An effective and efficient solution.



Enhancing outcomes for
patients and their caregivers:

Hill-Rom


The MetaNeb® System Oscillation and Lung Expansion (OLE) Therapy

The MetaNeb® System OLE therapy is designed to mobilize retained secretions, to provide lung expansion therapy, and to deliver medicated aerosol for the treatment and prevention of pulmonary atelectasis. It also has the ability to provide supplemental oxygen when used with compressed oxygen.


OLE therapy maximizes efficiency for patients and clinicians by combining three treatments into a single integrated therapy. It may reduce therapy time to just 10 minutes,* and eliminate the need to switch devices.

OLE therapy delivered through a single unit:

- Simple to “connect and go” design.
- Single patient use (SPU) circuit includes mouthpiece, nebulizer, mask/trach adapter, and in-line CHFO mode.
- Quickly switch between therapy cycles.
- Easily adjustable flow, pressure and percussive rate.




POST-OPERATIVE PATIENTS ARE AT RISK OF PULMONARY COMPLICATIONS.



UP TO 40%
OF POST-SURGICAL PATIENTS
EXPERIENCE PPC.¹

Developing a pulmonary complication can increase hospital length-of-stay (LOS), ICU and hospital readmissions, mortality and healthcare costs.¹

EVIDENCE SHOWS THAT LUNG EXPANSION TECHNIQUES CAN HELP.



Guidelines recommend the use of lung expansion therapies with evidence showing 50% reduction of PPCs.^{1,2}



Preventing PPCs can reduce associated cost per patient by up to 92%.¹

The MetaNeb® System provides patients with OLE, an effective and consistent therapy to prevent and treat pulmonary atelectasis.

- ✓ Flexible 3-1 therapy enables seamless delivery to meet patient needs:
 - Aerosol Delivery
 - Secretion clearance
 - Lung expansion
- ✓ Mechanically driven requiring minimal patient effort for effective therapy.
- ✓ Caregivers' consistent engagement and administration ensures compliance of the therapy delivery.

Providing effective pulmonary therapies for critical care patients leading to improved clinical outcomes.


**50%
REDUCTION**
IN PULMONARY
COMPLICATIONS.¹

**UP TO
1 DAY
REDUCTION**
IN ICU LENGTH OF STAY
WITH LUNG EXPANSION
THERAPY.²

**UP TO
2 DAY
REDUCTION**
IN HOSPITAL LENGTH
OF STAY WITH LUNG
EXPANSION THERAPY.²

The MetaNeb® System 10-Minute OLE Therapy Cycle

ALTERNATING CYCLES OF CPEP AND CHFO COMBINED WITH AEROSOL DELIVERY HELP MAXIMIZE THERAPY EFFECTIVENESS.



Introduces CHFO therapy immediately after lungs have been expanded through CPEP.

Aerosol delivered in both lung expansion and secretion clearance.

*Therapy times may differ depending on patient ordered therapies.
CHFO = Continuous High Frequency Oscillation
CPEP = Continuous Positive Expiratory Pressure



What does a MetaNeb® System patient look like?

Patient Populations Benefiting from the MetaNeb® System OLE Therapy:

Post-operative, trauma, spinal cord injuries, neuromuscular, chronic pulmonary conditions, pneumonia, emergency department and bariatric.



Assessing a Patient for OLE Therapy

EXCESSIVE SECRETION PRODUCTION

- Sputum production high
- Evidence of retained secretions in the presence of an artificial airway

INEFFECTIVE COUGH

- Inability to clear secretions
- Inability to take a deep breath (e.g., from incisional pain, muscle weakness)

INADEQUATE LUNG EXPANSION

- Abnormal chest x-ray
- Presence of atelectasis – clinically significant



Three therapies. One device.
An effective and efficient solution.

Hill-Rom is a leading global medical technology company with more than 10,000 employees worldwide. We partner with health care providers in more than 100 countries, across all care settings, by focusing on patient care solutions that improve clinical and economic outcomes in five core areas: **Advancing Mobility, Wound Care and Prevention, Patient Monitoring and Diagnostics, Surgical Safety and Efficiency and Respiratory Health**. Hill-Rom's people, products and programs work towards one mission: **Every day, around the world, we enhance outcomes for patients and their caregivers.**

References

1. Restrepo R, et al. (2015). Current challenges in the recognition, prevention and treatment of perioperative pulmonary atelectasis. *Expert Reviews. Respir. Med.* 9(1), 97-107.
2. Qaseem A, et al. (2006). Risk Assessment for and Strategies To Reduce Perioperative Pulmonary Complications for Patients Undergoing Noncardiothoracic Surgery: A Guideline from the American College of Physicians. *Ann Intern Med.* 144, 575-580.

Hill-Rom reserves the right to make changes without notice in design, specifications and models. The only warranty Hill-Rom makes is the express written warranty extended on the sale or rental of its products.

©2019 Hill-Rom Services PTE Ltd. ALL RIGHTS RESERVED.
198891 rev 2 27-AUG-2019 ENG – US

For further information about this product or a service, please contact your local Hill-Rom representative or visit our webpage:

800.426.4224

respiratorycare.hillrom.com